Overview

An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2029-04-30
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of HRS-4642 in combination with immunotherapy and chemotherapy in borderline resectable, locally advanced/metastatic pancreatic cancer
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Zhongshan Hospital